NDC 50242-145

PERJETA

Pertuzumab

PERJETA is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Genentech, Inc.. The primary component is Pertuzumab.

• Product ID: 50242-145_3aeaf488-7922-4a1f-9d6e-2c921aeb1e08
• NDC: 50242-145
• Product Type: Human Prescription Drug
• Proprietary Name: PERJETA
• Generic Name: Pertuzumab
• Dosage Form: Injection, Solution, Concentrate
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2012-06-08
• Marketing Category: BLA / BLA
• Application Number: BLA125409
• Labeler Name: Genentech, Inc.
• Substance Name: PERTUZUMAB
• Active Ingredient Strength: 30 mg/mL
• Pharm Classes: HER2/neu Receptor Antagonist [EPC],HER2/Neu/cerbB2 Antagonists [MoA]
• NDC Exclude Flag: N
• Listing Certified Through: 2021-12-31

Packaging

NDC 50242-145-01

1 VIAL, SINGLE-USE in 1 CARTON (50242-145-01) > 14 mL in 1 VIAL, SINGLE-USE

• Marketing Start Date: 2012-06-08
• NDC Exclude Flag: N
• Sample Package?: N

NDC SPL Data Element Entries

NDC 50242-145-01 [50242014501]

PERJETA INJECTION, SOLUTION, CONCENTRATE

• Marketing Category: BLA
• Application Number: BLA125409
• Product Type: HUMAN PRESCRIPTION DRUG
• Billing Unit: ML
• Marketing Start Date: 2012-06-08

Drug Details

Active Ingredients

Ingredient	Strength
PERTUZUMAB	30 mg/mL

OpenFDA Data

• SPL SET ID: 17f85d17-ab71-4f5b-9fe3-0b8c822f69ff
• Manufacturer:
  • Genentech, Inc.
• UNII:
  • K16AIQ8CTM
• RxNorm Concept Unique ID - RxCUI:
  • 1298948
  • 1298953

Pharmacological Class

• HER2/neu Receptor Antagonist [EPC]
• HER2/Neu/cerbB2 Antagonists [MoA]